Serum Uric Acid Concentration in Overweight and Obese Women with Polycystic Ovary Syndrome / Nivelul acidului uric la femeile supraponderale și obeze cu sindromul ovarelor polichistice

Open access


Background: Women with polycystic ovary syndrome (PCOS) are at high risk for the development of diabetes mellitus, hypertension and coronary heart disease. Due to the inverse correlation between serum uric acid and insulin sensitivity, the measurement of uric acid may provide a marker of insulin resistance. Objective: To establish the relationship between uric acid and markers of insulin resistance in obese and overweight women with PCOS. Methods: Serum uric acid levels were measured in 38 PCOS obese and overweight patients and 30 controls matched for age and body mass index (BMI). Anthropometric variables, plasma glucose and insulin levels were measured. Insulin resistance was evaluated by homeostasis model assessment (HOMA-IR). Results: No statistically significant differences in uric acid levels between PCOS and non-PCOS women were found. Serum uric acid levels were positively correlated with BMI, waist circumference, insulin and HOMA. Following the use of stepwise linear regression analysis, BMI was the only parameter retained by the regression model, responsible for 42.1% of the variability of serum uric acid levels. Conclusions: In PCOS women obesity seems to be the main determinant of plasma uric acid levels. Insulin and HOMA are also involved to a lesser extent, but their role remains to be clarified by further studies.

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9. DOI: 10.1210/jc.2003-032046

2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8. DOI: 10.1210/jc.85.7.2434 DOI: 10.1210/jcem.85.7.6682

3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-6. DOI: 10.1056/NEJMra041536

4. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61. DOI: 10.1056/ NEJM199509283331307

5. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68(5):209-17. DOI: 10.1159/000101538

6. Kousta E, Tolis G, Franks S. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences. Hormones 2002;4(3):133-147. DOI: 10.14310/horm.2002.11151

7. Cucuianu M, Brudasca I. Gout, hyperuricemia and the metabolic syndrome. Rev Romana Med Lab. 2012;20(3):199-206.

8. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42. DOI: 10.1016/j.semnephrol. 2004.09.007

9. Vuonnen-Markkola H, Yki-Jamnen H. Hyperuncemia and insulin resistance. J Clin Endocrinol Metab. 1995;78:25-9. DOI: 10.1210/jcem.78.1.8288709

10. Antilla L, Rouru J, Penttila T, Irjala K. Normal serum uric acid concentrations in women with polycystic ovary syndrome. Hum Reprod. 1996;11:2405-7. DOI: 10.1093/oxfordjournals.humrep.a019124

11. Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Serum uric acid concentration as a non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Rep. 2008;23(7):1594-601. DOI: 10.1093/humrep/den095

12. Quinonez Zarza C, Silva Ruiz R, Torres Juarez JM. Obesity, arterial hypertension, metabolic disorders, and polycystic ovary syndrome. Ginecol Obstet Mex. 2000;68:317-22.

13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004

14. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-26. DOI: 10.1016/j.amjmed.2005.03.043

15. Johnson R, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-90. DOI: 10.1161/01.HYP.0000069700.62727.C5

16. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932-5. DOI: 10.1016/j.amjcard. 2004.06.032

17. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-6. DOI: 10.1161/01.CIR.0000022140.61460.1D

18. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030. DOI: 10.1210/er.2011-1034

19. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628-37. DOI: 10.1210/jc.2012-3908

20. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab. 2013;98:2581-8. DOI: 10.1210/jc.2013-1161

21. Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008;69(1):52-60. DOI: 10.1111/j.1365-2265.2007.03145.x

22. Ketel IJG, Stehouwer CDA, Serne EH, Korsen TJM, Hompes PGA, Smulders YM, et al. Obese but not normal- weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab. 2008;93(3):3365-72. DOI: 10.1210/jc.2008-0626

23. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59(2):141-54. DOI: 10.1097/01.OGX.0000109523.25076.E2

24. Tsilchorozidou T, Overton C, Conway G. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60(1):335-45. DOI: 10.1046/j.1365-2265.2003.01842.x

25. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78(8):773-6. DOI: 10.1016/j.steroids. 2013.04.009

26. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357-63. DOI: 10.1210/jc.2005-2430

27. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: result of a 31 year follow-up study. Hum Fertil. 2000;3(2):101-5. DOI: 10.1080/1464727002000198781

28. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(2):112-26. DOI: 10.1093/humupd/dmr046

29. Vryonidou A, Papatheodorou A, Tavridou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(5):2740-6. DOI: 10.1210/jc.2004-2363

30. Rizzo M, Berneis K, Herberger M, Pepe I, Di Fede G, Rini GB, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod. 2009;24(9):2286-92. DOI: 10.1093/humrep/dep121

31. Barber TM, McCarthy MI, Wass AH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65(2):137-45. DOI: 10.1111/j.1365-2265.2006.02587.x

32. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232-9.

33. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulinresistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-74. DOI: 10.2337/diabetes.38.9.1165 DOI: 10.2337/diab.38.9.1165

34. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators of inflammation vol. 2010, article ID 758656, doi:10.1155/2010/758656 Hindawi Publishing Corporation. DOI: 10.1155/2010/758656

35. Chen X, Jia X, Qiaol J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 2013;50:R21-R37. DOI: 10.1530/JME-12-0247

36. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol. 2002;2:126-30. DOI: 10.1016/S1471-4892(02)00143-1

37. Vizzotto L, Vartemati M, Marinello E, Leoncini R, Pagani R, Pizzichini M. Effect of testosterone on purine metabolism and morphometric parameters in the rat liver. Mol Cell Endocrinol. 1996;119:123-7. DOI: 10.1016/0303-7207(96)03797-5

38. Marinello E, Leoncini R, Terzouli L, Vannoni D, Porcelli B, Resconi G. Effect of testosterone on purine nucleotide metabolism in rat liver. Horm Metab Res. 2004;36:614-9. DOI: 10.1055/s-2004-825923

39. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow- up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404-10. DOI: 10.1001/jama.283.18.2404

Revista Romana de Medicina de Laborator

Romanian Journal of Laboratory Medicine

Journal Information

IMPACT FACTOR 2017: 0.400
5-year IMPACT FACTOR: 0.320

CiteScore 2017: 0.31

SCImago Journal Rank (SJR) 2017: 0.144
Source Normalized Impact per Paper (SNIP) 2017: 0.195


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 178 177 16
PDF Downloads 55 55 7